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Abstract
Ribosome-inactivating proteins (RIPs) are enzymes (3.2.2.22) that possess N-glycosilase activity that irreversibly inhibits
protein synthesis. RIPs have been found in plants, fungi, algae, and bacteria; their biological role is still under investigation,
even if it has been recognized their role in plant defence against predators and viruses. Nevertheless, several
studies on these toxins have been performed to evaluate their applicability in the biomedical field making RIPs
selectively toxic towards target cells. Indeed, these molecules are extensively used to produce chimeric biomolecules,
such as immunotoxins or protein/peptides conjugates. However, to date, clinical use of most of these bioconiujates
has been limited by toxicity and immunogenicity. More recently, material sciences have provided a wide range of
nanomaterials to be used as excellent vehicles for toxin-delivery, since they are characterized by improved stability,
solubility, and in vivo pharmacokinetics. This review discusses progresses in the development of RIPs bioconjugates,
with particular attention to the recent use of nanomaterials, whose appropriate design opens up a broad range of
different possibilities to the use of RIPs in novel therapeutic approaches in human diseases.
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Background
Ribosome-inactivating proteins (RIPs) belong to a class
of enzymes identified in plants, fungi, algae, and
bacteria. RIPs exhibit rRNA N-β-glycosilase activity,
which leads to the cleavage of an adenine residue at a
conserved site of the 28S rRNA [1], Fig. 1a. Cleavage
of this single N-glycosidic bond is irreversible and
interferes with the association between the elongation
factors and ribosome, causing the inhibition of protein
synthesis [2].
In addition to their cytotoxic effects, many RIPs have
additional biological actions, not necessarily related to
N-glycosilase activity, on cells and/or on organisms.
Beyond that, it has been reported that some RIPs possess
additional enzymatic activities on different substrates
that include adenine polynucleotide glycosylase activity,
phosphatase activity on lipids as well as chitinase, DNase
and superoxide dismutase activities [3–5].
RIPs can be categorized into two groups, distinguishable
in monomeric type 1 RIPs and dimeric type 2 RIPs. These
latter are composed by a chain that exhibits the toxic
rRNA N-glycosilase activity (A-chain) and by a lectin
chain (B chain) as schematized in Fig. 1b. Accentuated
toxicity of type 2 RIPs respect to type 1 RIPs is due to rec-
ognition, mediated by A-chain, of mammalian cell surface
galactose moieties. The absence of the lectin chain signifi-
cantly limits the access of type 1 RIPs into cells, determin-
ing a consequent lower cytotoxicity. Beyond these, some
non-canonical RIPs, such as tetrameric ebulin [6, 7] or
proteolytic activated maize b-32 [8] were also found.
Different reports have highlighted the existence of a
close correlation between RIPs cytotoxicity and intracellu-
lar routing, which may vary between different cell types
depending on: (i) expression of different types of binding
molecules (ligands) on cell surface [9, 10]; (ii) sorting of
RIP-ligand complexes to different compartments [11, 12];
(iii) availability of various pathways for the transport of
the toxin to the cytosolic compartment [13–15].
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These considerations are also corroborated by the ex-
istence of non-toxic RIPs, identified in some plants, that
despite having N-glycosilase activity are non-toxic, since
they are degraded as a result of an intracellular routing
different from that of toxic type 2 RIPs [7, 16].
Generally, RIPs enter the cell by first binding to
cell surface receptors, then crossing the cell
membrane via endocytosis and, finally, translocate
into the cytosol by an intracellular compartment.
Type 2 RIPs (e.g. ricin), across the membrane via
endocytosis, after binding to galactose moieties, and
are delivered from Golgi network to the endoplasmic
reticulum (ER) by retrograde vesicular transport.
Once in the ER lumen, the A and B chains are
dissociated and finally the active A chain portion is
directed to the cytoplasm [11, 13].
On the contrary type 1 RIPs, devoid of lectin B-chain,
once internalized, are delivered to the cytoplasm
through a Golgi independent route, thereby making their
uptake by cells more difficult [9, 14].
However, the possibility of selectively directing RIPs to
target cells opens huge applications in medicine [17–19],
as demonstrated by targeted RIP based toxic prepara-
tions used in a number of clinical trials and in a very
large number of preclinical studies [20, 21].
Review
RIP based immunotoxins
Chimeric molecules obtained combining antibody
portion and specific toxins are known as immunotoxins:
bifunctional macro-molecules that are based on intracel-
lular toxin action to kill target cells [22]. The progress of
recombinant antibody engineering and protein fusion
technology has led to rapid expansion of drug-targeting
devices with superior antigen binding and pharmacoki-
netic properties (Fig. 2a) [23]. Nowadays immunotoxins
are considered powerful immune-bullets against cancer
cells, in immune regulation and in the treatment of viral
























Fig. 1 Enzymatic and structural properties of RIPs. a RIPs recognize α-sarcin/ricin loop (SRL), highlighted in grey, of rRNA 28S on ribosomes. Depurination
of A4234 (see text) by N-glycosilase activity inhibits role of eukaryotic elongation factor 2 (eEF2) in the promotion of the GTP-dependent translocation of
the nascent protein chain from the A-site to the P-site of the ribosome, with consequent arrest of protein synthesis. b Structural representation of type 1
RIPs (single enzymatic chain) and type 2 RIPs (dimeric protein consisting of an enzymatic chain and a lectin domain)
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Since methods of conjugations of antibodies to RIPs
can theorically affect the activity of immunoconjugates
in vivo, different critical strategies have been performed
to maximize the release of active toxins in the target
cells [26, 27].
One of most approaches used in RIP based immuno-
conjugates synthesis for tumor cells, the latter typically
characterized by a hypoxic state induced by an enhanced
activity of reductive enzymes, is based on the choice of
reducible disulfide cross-linker between RIP moiety and
antibodies. In this way redox state of target cell should
able to induce a reduction of RIP based immunoconju-
gate after its cell internalization, with consequent release
of type 2 catalytic active A chain or type 1 RIP.
An alternative approach, conceived for RIPs lacking
free sulphydryls (e.g. gelonin, PAP, saporin etc.) and used
also to carrier whole type 2 RIPs, was based on the use
of specific cross-linker that bind reactive functional
groups present on proteins as primary amines,
carbonyls, carbohydrates and carboxylic acids generating
new sulphydrylic groups. To carry out this strategy,
conjugate preparation required a preliminary separate
derivatization of both toxin and antibody; subsequently
newly inserted groups on two molecules can react to
produce, by disulfide bridges, a stable conjugate popula-
tion [28]. Some of the most used heterobifunctional
crosslinking agents for immunotoxin conjugation by S-S
disulfide, are SPDP [N-succinimidyl 3-(2-pyridyldithio)
propionate]; SATA, [S-(N-succinimidyl) thioacetate];
SMPT, [(N-succinimidyloxy carbonyl)-1-methyl-1-(2-
pyridyldithio) toluene] [26, 28].
Nevertheless, any problems were related to these
approaches, due to possible premature reduction of
immunoconjugates, which induced negative effects as:
1. competition between free antibodies and immuno-
conjugates in the recognition of target sites; 2. decrease
of intracellular cytotoxic RIPs; 3. increase of side effects
on several organs (e.g. liver). Other forms of heterobi-
functional crosslinkers to create toxic conjugates not re-
stricted by the disulphide bridge requirement are based
on the ability to create stable tioether linkages (S-C).
SMCC, [N-succinimidyl 4-(maleimidomethy1) cyclohex-
anecarboxylate] and MBS [3-maleimidobenzoic acid N-
hydroxysuccinimide ester] are frequently used to form
not cleavable thioether bonds between type 2 RIPs and
antibodies.
The first RIP based immunotoxins were generated by
coupling a deglycosylated type 1 or an A-chain from
type 2 RIP with a native antibody by using specific
cross-linking agents reacting with cysteinyl residues of
both molecules [29, 30]. Subsequently, novel RIP based
immunotoxins were produced and characterized to im-
prove pharmacokinetics and reduce side effects; they
were obtained by continuous development of recombin-
ant DNA techniques and optimization of expression sys-
tems, using yeast, bacteria, or eukaryotic cell cultures
(CHO cells, insect cells, etc.). The design of these novel
RIP based immunotoxins required two critical steps: (i)
planning and construction of recombinant antibody frag-
ments (with reduced molecular weight); improvement of
expression and purification methodology [31, 32]. The
production of these compact immunotoxins also fulfilled
the aim to stabilize the toxin during its intracellular
routing (delivery through endosomes-Golgi-lysosomes)
preventing its proteolytic degradation [21].
On the basis of above described considerations, an
excellent RIP prototype, used to build immunotoxins
targeted to different malignant cells or solid tumors, was
type 1 RIP saporin-S6. Indeed saporin-S6 immunoconju-
gates evidenced good structural and functional charac-
teristics, such as high resistance to denaturation and
proteolysis, as well as strong catalytic efficacy coupled to
a very low cytotoxicity on normal cells [3, 9].
Advances in antibody technology to avoid heterogeneity,
improve tumor penetration and reduce production com-
plexity of immunotoxins, have enabled the development
of new generations of RIP based immunoconjugates.
Starting from monoclonal antibody to the smallest
unit of immunoglobin molecules (e.g. single chain
fragment variable - scFv) several RIP based immuno-
toxins have been designed against several targets and
in most cases used in pre-clinical studies, leading to
promising outcomes [20, 33–35].
It is noteworthy that a further technology was success-














Fig. 2 Putative RIP based conjugates. a ImmunoRIPs obtained fusing
RIPs to antibody (left) or minibody, as scFv (right). b Alternative
bioconiujates obtained fusing RIPs to receptors (left), cellular ligands
(center) and protease inhibitors (right)
Pizzo and Di Maro Journal of Biomedical Science  (2016) 23:54 Page 3 of 8
photochemical internalization technology (PCI) [36].
This technology is based on amphiphilic photosensi-
tizers, which accumulate in the endocytic membranes.
Light exposure causes generation of ROS and subse-
quent increased permeability of the endocytic mem-
branes, thus allowing improved trafficking of agents to
the cytosol.
Protein or peptides conjugated with RIPs
Members of RIPs have been either fused or chem-
ically conjugated to different suitable carriers, such as
cell-binding ligands, protease inhibitors, hormones,
etc., in order to create specific bifunctional cytotoxic
agents (Fig. 2b).
Even for design and production of these new types of
conjugates, saporin-S6 was used as a prototype. Indeed,
this type 1 RIP was successfully fused to urokinase re-
ceptor (uPAR) to obtain a very effective bifunctional
chimeric molecule with a strong cytotoxicity, specifically
to uPAR expressing cells, whereas the conjugate was
found not to be effective on cell lines devoid of
uPARs [37].
In alternative reports, as a carrier in the design of con-
jugates it was used transferrin, a protein involved in iron
uptake by cells. Transferrin is an iron-binding glicopro-
tein able to carry two iron ions in the ferric form (Fe3+)
into the cell, upon binding to its receptor. Transferrin
receptor, widely distributed in different cell types, is usu-
ally overexpressed in malignant cells. Artificial conju-
gates consisting of RIPs (e.g. saporin-S6, ricin, etc.)
conjugated to transferrin revealed, although by different
mechanisms of intracellular routing, a selective cytotox-
icity on various cancerous or malignant cell lines [9].
Transferrin receptor was used as malignant cell target
also to build RIP based conjugates containing a peptide
carrier. A meaningful example is represented by curcin,
a broad cytotoxic type 1 RIP from the seeds of Jatropa
curcas L.. As this protein is able to inhibit tumor cell
proliferation and promote cell apoptosis, it was used to
build a conjugate in which, to enhance the targeting of
its anti-tumor ability, a transferrin receptor peptide
(TfRBP), was fused with it. This peptide was screened by
phage display technology [21] and found to be a strong
affinity for tumor cells over-expressing the transferrin
receptor. Resulting conjugate curcin-TfRBP9 was found
to significantly inhibit the proliferation of HepG2 cells
over-expressing transferrin receptors and to have lower
inhibitory effects on SKBR-3 cells expressing transferrin
receptors at low levels [21].
Other representative chimeric conjugates were obtained
by using the gonadotropin-releasing hormone (GnRH)
as a carrier, since potent GnRH agonists and antago-
nists were widely used to treat different kind of repro-
ductive apparatus cancer. For this purpose, type 1 RIP
Pokeweed Antiviral Protein (PAP) was used, since it has
no toxicity to human sperm and on epithelial cells in
the female genital tract [38]. Treatment of GnRH
receptor-positive cells, as human endometrial, breast or
prostate cells, with the conjugate GnRH-PAP resulted
in dose dependent cytotoxicity, thus demonstrating that
other conjugates hormone/RIP could be used to specif-
ically deliver these toxins to cells that express appropri-
ate hormone receptors [39].
Other interesting fusion constructs generated with
RIPs involved gelonin, a type 1 RIP from Gelonium mul-
tiflorum L.. Gelonin based conjugates, obtained by fusing
it with different carriers, such as a cytokine (e.g. BLyS –
B lymphocyte stimulator), a transmembrane glycoprotein
kinase (e.g. Her2-protein encoded by a proto-oncogene)
or an angiogenic factor (e.g. VEGF- vascular endothelial
growth factor), showed a selective toxic action on tumor
cells and on solid tumors [40].
It has been widely reported that RIPs cytotoxicity
depends not only on the intracellular routing, but also on
the intrinsic resistance to proteolysis. Pioneering works
carried out on ricin free A chain [41] and saporin-S6 [3]
confirmed this hypothesis, because their mutants (ob-
tained by replacing surface residues with lysine residues),
despite not compromising their activity, structure, or
stability, significantly enhanced their susceptibility to pro-
teolytic degradation. Moreover, as it is not unusual to find
inhibitory protease modules in a multi-domain protein,
new approaches have been carried out to build RIPs based
chimeric proteins containing type 1 RIPs and protease in-
hibitor domains to enhance resistance to proteolysis dur-
ing their intracellular routing [42]. In this regard, recently
it has been described the characterization of a bifunctional
chimeric molecule composed by PD-L4 (a type 1 RIP iso-
lated from Phytolacca dioica L. summer leaves [43]) and
WSCI (a serine protease inhibitor isolated from endo-
sperm of hexaploid seeds of Triticum aestivum L.) [44].
This recombinant construct showed intact intrinsic activ-
ity of both domains (e.g. enzymatic activity and inhibitory
properties), and at the same time an enhanced selective
cytotoxicity on murine tumor cells. Similar results have
also been obtained by changing the anti-protease inhibi-
tory properties of WSCI domain [45].
Finally, a special mention has to be done to the use of
peptides as carrier of RIPs for the construction of conju-
gates. A novel conjugate was obtained by fusing MAP30, a
type 1 RIP from Momordica charantia L. and HBD, a cell
penetrating peptide identified in the heparin-binding
domain of human superoxide dismutase [46]. This fusion
construct revealed an enhanced selective cytotoxicity on
different tumor cell lines thanks to an efficient uptake
mediated by the peptide, the latter being a prototype of a
new class of short basic peptides that are revolutionizing
the way to deliver biomacromolecules.
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A different peptide, a human 36-aa neuropeptide widely
distributed in brain and peripheral tissues, named NPY,
has been used to build a conjugate with saporin-S6.
Authors reported that this conjugate selectively killed
NPY receptor-expressing neurons and, for this reason, it
has been used as a tool to study the central NPY neurocir-
cuitry involved in feeding behaviors [47].
RIPs conjugated with nanoparticles
In recent years, considerable efforts have been made in
the field of biomaterials providing increasing numbers of
platforms for the development of a wide range of smart
materials to control the delivery and release of specific
drugs [48–50]. For this purpose, synthetic nanomaterials,
including liposomes, polymers and inorganic nanoparti-
cles, have been designed [51–53] to provide improved
stability, solubility, and in vivo pharmacokinetics.
Owing to their intriguing features, such as size, shape
and biocompatibility, nanoparticles have been receiving
increased attention in the area of nano-drug delivery
systems, since a variety of drugs, proteins, antibodies,
peptides, etc. can be conjugated with them [54].
As nanoparticles are able to cross the blood brain
barrier, opening new perspectives to drug delivery into
the brain, and since their nanosize allows access into
the cell and in various cellular compartments, including
the nucleus, the development of various RIP-based plat-
forms has recently undergone a significant impetus
(Fig. 3a and b).
For example, curcin [55] was successfully used in the
construction of gold nanoparticles (AuNPs) conjugated
with folate and anti-transferrin antibody, to achieve a
dual targeted nano-formulation directed toward gliomas.
AuNPs are nanoparticles (in the range of 10–15 nm)
consisting of a gold core and a surface coating, modifi-
able to control particle stability, solubility and inter-
action with the biological environment. As well, the
ability of the AuNP surface to bind to thiols and amines
provides a convenient way to introduce reactive func-
tional groups to conjugate therapeutic agents. In this
case, AuNPs functionalized with PEG were preliminary
conjugated to anti-transferrin antibodies and subse-
quently subjected to reaction with hydrazine-activated
curcin. Authors revealed that this specific functionalized
nanoconjugate minimized the nonspecific systemic spread
of toxin molecules during circulation and maximize the
efficiently of tumor-targeted drug delivery. Besides, once
internalized, pH-sensitive hydrazone bonds guaranteed
the maximum release of curcin from nanoconjugate with
consequent efficacy of toxic action in the target glioma
cancer colonies [55].
An additional example is represented by hybrid col-
loidal nanosystems, consisting of lipid polymeric compo-
nents chemically amalgamated and highly compatible.
Lipid-polymer hybrid nanoparticles are core-shell nano-
structures comprising polymer cores and lipid/lipid-PEG
shells, which exhibit characteristics of both polymeric
nanoparticles and liposomes. In a recent work hybrid
solid lipid nanoparticles were prepared by a modified
lipid coacervation method. The latter is a procedure to
forming a liquid rich in polymer phase in equilibrium
with another liquid phase. In this case authors prepared
hybrid solid lipid nanoparticles composed by 1,2-Dis-
tearoyl-sn-glycero-3-phosphoethanolamine-N-maleimide
(PEG-2000) (DSPE-PEG-Mal), lecithin, stearic acid and
folate. When these lipid based nanoparticles were conju-
gated to curcin, they became a nano-formulation select-
ively active against gliomas cells [56].
In a further work it has been described a different
protein delivery strategy in which a new nanoconjugate has
been obtained by combinatorial design of cationic lipid like
materials, termed “lipidoids”, coupled with a reversible
chemical protein engineering approach [57]. Preparation of
lipidoids requires heating, in absence of solvent or
catalysts, of commercially available amines with lipophilic
acrylamides, acrylates, or epoxides. This simplified proced-
ure allows building a structurally diverse library of lipidoids
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Fig. 3 Innovative strategies to obtain a next generation of RIP based
conjugates. a Metal nanoparticles consisting of RIPs and agents that
drive resulting conjugate to cellular target; b Nanoconjugates obtained
by combinatorial design of lipid like materials termed “lipidoids”;
c Schematic representation of encapsulated RIPs in nanocapsules
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(acrylamide/acrylate/epoxide) of tails. Resulting crude
products can be directly used for in vitro delivery of
macromolecule of interest. Therefore, lipidoids offer two
significant advantages: a simple and economical chemical
synthesis and the possibility to develop libraries based on
peculiar diversities (e.g. structure, physic-chemical proper-
ties, size etc.). In the case of RIPs, starting from a library of
lipidoids synthesized through the ring opening reaction be-
tween 1,2-epoxyhexadecane and primary or secondary dif-
ferent aliphatic amines, a strong lipid-like nanoconjugated
has been obtained using saporin-S6. This nanoconjugate
was able to inhibit proliferation in vitro of various cancer-
ous cell lines, with IC50 values greatly decreased compared
to saporin alone, and was also found to abolish tumor
growth in a mouse model of breast cancer [57].
Recently, it has been reported the emergent possi-
bility to produce nanocapsules as efficient in vivo
drug delivery system, Fig. 3c [58]. In this framework,
also RIPs have proved to be optimal subject for this
novel nanotechnology, as demonstrated in a recent
paper where it has been reported the development of
new drug formulations based on encapsulation of
MAP 30 into chemically synthesized matrices of
zirconium egg- (EPC) and soy-phosphatidylcholines
(SPC). These matrices were obtained by mixing (EPC)
or (SPC) lipids in ZrCl4 aqueous solution [59] and
exhibited the plate like and granular aggregates with
diameters of about 70 nm. Subsequent encapsulation
of MAP30 produced strong toxic and antimicrobial
nanoparticles and a release of RIP dependent on
endogenous phospholipase A (PLA) activity [58].
A similar approach, by using type 1 RIP from Mirabilis
jalapa L. leaves, has been recently used by Wicaksono et
al. [60]. This RIP, easily degraded after administration,
shows strong cytotoxicity on breast cancer cell lines and a
negligible toxicity towards normal cells. In this work, the
authors incorporated this type 1 RIP into nanoparticles
conjugated with Anti-EpCAM antibodies and determined
its selective cytotoxicity against T47D breast cancer cells.
Nanoparticles were obtained by polyelectrolyte complex-
ation using low viscosity chitosan (β-(1,4)-linked 2-amino-
2-deoxy-β-D-glucose) and alginate (linear unbranched
polymer of (1-4’)-linked β-D-mannuronic acid and α-L-
guluronic acid residues) [61], then chemically conjugated
with anti-EpCAM antibody by carbodiimide reaction.
All mentioned examples reveal that developing cancer
targeted-therapy by using nanotechnology platform is very
promising, especially with active-targeting nanoparticles
[62]. It is widely reported that chemotherapeutic agents
delivered systematically can be enter both tumor and
critical organs (heart, lung, etc.) consequently determining
patient’s suffering, noted as systemic toxicity. Systemic
toxicity is the result of absorption and distribution of a
chemoterapic agent to a site (organs, tissues, etc.) distant
from its entry point of administration and it is the main
cause of cancer drugs failure and of therapies who seek to
differentiate between cancerous and normal cells [63].
Progressive development in active targeting smart nano-
particles and use of RIPs, in the construction of low dos-
age RIP based nanoconjugates, represent new possible
future directions in the construction of innovative nano-
systems aimed to mitigate or limiting system toxicity.
Conclusion
Today the pharmacology is no longer exclusively oriented
to the identification of “small molecules”, but also on
searching for a second line of bio-based chemotherapeutic-
conjugated, exploiting the engineering of recombinant pro-
teins as well as the protein technology. In particular, for
this reason, the pharmacology industries are exploring
several options, such as specific cellular targets or new
drug delivery methods.
In both cases, RIPs proved to be good prototypes, due
to their structures and toxicity. In this review, we
tracked a path from first RIP based conjugates to recent
RIP based nanoconstructs (Fig. 4), giving new emphasis
to the study of these special and “ancient” molecules,
which are essential natural defence elements in plant
organisms, but at the same time excellent candidates for
therapeutic applications in biomedical sciences.
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